Roche gifts blockbuster cancer drug to Galecto for new clinical partnership trial

Biotech company Galecto has partnered up with Roche, with the latter providing its cancer treatment Tecentriq free of charge for a mid-phase trial testing a combination of the blockbuster drug with one of three Galecto candidates. The deal is a significant cost saver for the Danish biotech company, which doesn't even have to surrender commercial rights for the potential combination treatment.

Hans Schambye, CEO at Galecto Biotech and chair at Danish Bio | Photo: Henriette Dan Bonde / PR

The Danish-Swedish firm Galecto Biotech, which is spearheded by President and CEO Hans Schambye, has entered into a partnership with one of the giants of the pharmaceutical industry.

Galector Biotech has made Roche a central player in the upcoming phase IIa trial, which is set to test the candidate GB1211 in combination with Roche's multi-blockbuster immunotherapy Tecentriq (atezolizumab) as a potential treatment for non-small cell lung cancer (NSCLC).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs